Prostate Cancer and Prostatic Diseases

Displaying 1 - 5 of 5
Zorko, N. A., Makovec, A., Elliott, A., Kellen, S., Lozada, J. R., Arafa, A. T., Felices, M., Shackelford, M., Barata, P., Zakharia, Y., Narayan, V., Stein, M. N., Zarrabi, K. K., Patniak, A., Bilen, M. A., Radovich, M., Sledge, G., El-Deiry, W. S., Heath, E. I., … Antonarakis, E. S. (2024). Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-024-00797-0
Publication Date
Galván, G. C., Macias, E., Sanders, S., Ramirez-Torres, A., Stock, S., You, S., Riera, C. E., Tamukong, P., Smith-Warner, S. A., Genkinger, J. M., Luthringer, D. J., Freeman, M. R., & Freedland, S. J. (2023). The effects of glycemic index on prostate cancer progression in a xenograft mouse model. Prostate Cancer and Prostatic Diseases, 27(2), 348–354. https://doi.org/10.1038/s41391-023-00769-w
Publication Date
Chestang, J., Wang, S., & Yu, J. B. (2023). Prostate cancer in New York City: impact of neighborhood level social determinants of care. Prostate Cancer and Prostatic Diseases, 26(3), 628–630. https://doi.org/10.1038/s41391-023-00687-x
Publication Date
Margolis, E., Brown, G., Partin, A., Carter, B., McKiernan, J., Tutrone, R., Torkler, P., Fischer, C., Tadigotla, V., Noerholm, M., Donovan, M. J., & Skog, J. (2021). Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies. Prostate Cancer and Prostatic Diseases, 25(2), 296–301. https://doi.org/10.1038/s41391-021-00456-8
Publication Date
Drake, C. G., Pachynski, R. K., Subudhi, S. K., McNeel, D. G., Antonarakis, E. S., Bauer, T. M., Lauer, P., Brockstedt, D., Patricia, D., Wade, M., Zudaire, E., Bandyopadhyay, N., Parasrampuria, D. A., Girgis, S., Mason, G. E., Knoblauch, R. E., Stone, N., Infante, J. R., Gottardis, M. M., & Fong, L. (2021). Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 25(2), 219–228. https://doi.org/10.1038/s41391-021-00402-8
Publication Date